48th week of 2014 patent applcation highlights part 39 |
Patent application number | Title | Published |
20140348830 | INTERLEUKIN-6 RECEPTOR BINDING POLYPEPTIDES - The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor. | 2014-11-27 |
20140348831 | ANTI-PROSTATE CANCER ANTIBODIES AND METHODS OF DETECTION AND TREATMENT OF PROSTATE CANCER USING THE SAME - Disclosed herein are antibodies that detect a lipid-like antigen on prostate cancer cells and methods of detecting and treating prostate cancer using the same. | 2014-11-27 |
20140348832 | INHIBITORS OF T-CELL ACTIVATION - The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex. | 2014-11-27 |
20140348833 | NOVEL METHODS AND ANTIBODIES FOR TREATING CANCER - The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein
| 2014-11-27 |
20140348834 | IL-17 BINDING PROTEINS - Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. | 2014-11-27 |
20140348835 | ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF - Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity. | 2014-11-27 |
20140348836 | ANTI-CD40 ANTIBODIES, USES AND METHODS - The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10 | 2014-11-27 |
20140348837 | BINDING MOLECULES FOR BCMA AND CD3 - The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule. | 2014-11-27 |
20140348838 | IL-1 BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 2014-11-27 |
20140348839 | MODIFIED POLYPEPTIDES FOR BISPECIFIC ANTIBODY SCAFFOLDS - The technology relates in part to engineered antibodies. In particular, multispecific engineered antibodies. Such antibodies can be utilized for diagnostic and therapeutic applications in some aspects. | 2014-11-27 |
20140348840 | METHOD OF TREATING AND REDUCING THE RISK OF ACUTE MYELOGENOUS LEUKEMIA - The present invention relates to methods and compositions for treating and reducing the risk of Acute Myelogenous Leukemia (AML). In particular, the invention provides methods for identifying novel treatments for AML based on reproducible and detectable changes in AML1-ETO acetylation. The present invention further provides methods of using these treatments. | 2014-11-27 |
20140348841 | ANTI-GITR ANTIBODIES - Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders. | 2014-11-27 |
20140348842 | TIM-3 LIGANDS AND METHODS THEREOF - The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses. | 2014-11-27 |
20140348843 | APOE IMMUNOTHERAPY - The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases. | 2014-11-27 |
20140348844 | NEUTRALISING ANTIBODIES TO THE MAJOR EXOTOXINS TCDA AND TCDB OF CLOSTRIDIUM DIFFICILE - This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of | 2014-11-27 |
20140348845 | ION EXCHANGE MEMBRANE CHROMATOGRAPHY - Methods of enhancing efficiency of downstream chromatography steps for purification of proteins comprising: (a) passing a composition comprising a polypeptide of interest and various contaminants through an ion exchange membrane, wherein the polypeptide and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH sufficiently distinct from the pi of the polypeptide to enhance the charge of the polypeptide and a low ionic strength effective to prevent the shielding of charges by buffer ions, which cause the membrane to bind the polypeptide and at least one contaminant, (b) overloading the ion exchange membrane such that at least one contaminant remains bound to the membrane while the polypeptide of interest is primarily in the effluent; (c) collecting the effluent from the ion exchange membrane comprising the polypeptide of interest; (d) subjecting the membrane effluent comprising the polypeptide of interest to a purification step of similar charge as the previous membrane, and (e) recovering the purified polypeptide from the effluent of the charged ion exchange chromatography purification step. | 2014-11-27 |
20140348846 | ANTI-HLA CLASS-IB ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) USEFUL AS THERAPEUTIC IVIG MIMETICS AND METHODS OF THEIR USE - Provided herein are compositions comprising anti-HLA-Ib antibodies (monoclonal, mixed monoclonal, recombinant, chimeric, humanized or human antibodies) as IVIg mimetics and methods for using the same for the prevention, treatment, therapy and/or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-HLA-Ib antibodies strongly mimic IVIg in immunoreactivity to HLA class Ia (HLA-A, HLA-B and HLA-Cw) and Ib antigens (HLA-E, HLA-F and HLA-G). In certain embodiments, the anti-HLA-Ib antibodies strongly mimic IVIg in immunomodulatory or immunosuppressive activities. Methods are also provided herein to induce production of polyclonal anti-HLA-Ib antibodies in cancer patients for restoring anti-tumor activities of CD8+ T cells and NK cells, by active specific immunotherapy. | 2014-11-27 |
20140348847 | ANTIBODIES AGAINST HUMAN IL-12 - The present invention relates to novel p75 heterodimer specific anti-human IL-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human IL-12 bioactivity than known heterodimer specific IL-12 monoclonal antibodies. The heterodimer specific antibodies recognize one or more epitopes of the human IL-12 p75 heterodimer, but do not bind to the p40 subunit alone. The heterodimer specific IL-12 antibodies neutralize rhesus monkey IL-12 bioactivity with a potency similar to their potency for neutralizing human IL-12 bioactivity making them useful IL-12 antagonists for in vivo studies in the rhesus monkey. | 2014-11-27 |
20140348848 | ANTI-IL-1BETA (INTERLEUKIN-1BETA) ANTIBODY-BASED PROPHYLACTIC THERAPY TO PREVENT COMPLICATIONS LEADING TO VASO-OCCLUSION IN SICKLE CELL DISEASE - This invention generally relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to also as “IL-1beta Compounds”) in a therapy preventing manifestations and especially complications leading to subsequent damages, such as vaso-occlusion, in individuals being threatened by sickle cell disease (that is, especially homozygous HbS gene carriers, heterozygotes with sickle-beta-thalassemia with an SCD supporting combination of HbS gene and beta-thal gene, an individual with one sickle cell gene and one null alleleor an individual with hemoglobin SC disease). | 2014-11-27 |
20140348849 | Compounds and Method for Modulating Inflammatory Reactions - The present invention relates to compounds and methods for modulating, reducing or inhibiting, inflammatory reactions in a patient. Particularly, inflammatory reactions that are targeted by the present invention are cell migration, secretion of toxic products and proteolysis at a site of inflammation. Reduction of inflammation manifestations and reactions occurs by using an anti-S100 polynucleotide or polypeptide inhibitor or antagonist, which is essentially targeted against S100A8, S100A9 or S100A12, alone or in combination with other inhibitors of chemokines or immune modulating products. | 2014-11-27 |
20140348850 | METHOD FOR REDUCING BLOOD PRESSURE USING INHIBITORS OF PLASMA KALLIKREIN - The present invention relates to methods of reducing blood pressure in a subject by administering a plasma kallikrein inhibitor. | 2014-11-27 |
20140348851 | ANTIBODIES DIRECTED AGAINST INFLUENZA - Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided. | 2014-11-27 |
20140348852 | METHOD FOR MAKING PRECIPITATED PARTICLES - The present invention relates to the provision of a novel method for preparing dry amorphous precipitated protein particles. In particular to a method provides amorphous precipitated protein particles suitable for use in dry protein formulations which can be reconstituted to provide clear, foam free concentrated protein solutions. | 2014-11-27 |
20140348853 | METHODS OF TREATING RICKETTSIA USING EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) INHIBITORS - Embodiments of the invention are directed to compounds that inhibit an activity of EPAC proteins and methods of using the same. | 2014-11-27 |
20140348854 | HE4 Based Therapy For Malignant Disease - The invention provides compositions and methods for utilizing human epididymal secretory protein E4 (HE4) in the prevention and treatment of cancer and other human diseases. | 2014-11-27 |
20140348855 | ANTIBODY FORMULATIONS - Formulations comprising an anti-IL-13 antibody are provided, including pharmaceutical formulations and methods of using such formulations. | 2014-11-27 |
20140348856 | IL-17 BINDING PROTEINS - Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. | 2014-11-27 |
20140348857 | METHODS OF DIAGNOSIS AND TREATMENT OF ENDOPLASMIC RETICULUM (ER) STRESS-RELATED CONDITIONS - The present invention relates to methods for treating endoplasmic reticulum (ER) stress-related conditions (e.g., cancer, protein folding/misfolding disease, diabetes mellitus) and for identifying compounds for treating ER stress-related conditions in a subject (e.g., a human). The invention also provides methods for diagnosing an ER stress-related condition in a subject and kits for the treatment of same. | 2014-11-27 |
20140348858 | MONOCLONAL ANTIBODIES SPECIFIC FOR THE M2-1 ANTIGEN OF RESPIRATORY SYNCYTIAL VIRUS (RSV) - The use of monoclonal antibodies specific for respiratory syncytial virus (RSV). Specifically, to a monoclonal antibody IgG2A secreted by the cell line of 8A4/G9 hybridoma specifically directed to the M2-1 viral antigen, which is associated with the nucleocapside of the virus. The antibodies can be used for assays for the detection and/or determination of RSV infection. The antibodies are in the pure state and do not contain any other contaminating biological material. A method for preventing and treating the infection caused by respiratory syncytial virus (RSV) in a given host is provided, including the administration of a composition containing the monoclonal antibodies secreted by the 8A4/G9 hybridoma in sufficient doses to prevent the disease. The antibody can be humanized in order to minimize the possibility of an immune response against the same in the patient. In addition, it can be used to obtain any pharmaceutical form of the formulation of the monoclonal antibodies secreted by the 8A4/G9 hybridoma, which are suitable for the treatment or prevention of the disease caused by RSV. It also provides methods for detection and diagnosis of RSV viral antigens in biological samples using the monoclonal antibodies produced and secreted by cells of the 8A4/G9 hybridoma. | 2014-11-27 |
20140348859 | COMPOSITIONS, METHODS AND USES FOR ALPHA-1 ANTITRYPSIN FUSION MOLECULES - Compositions of and methods for making and using alpha-1 antitrypsin (AAT) fusion molecules or peptide derivatives thereof are disclosed. The compositions and methods relate to generating an AAT fusion molecule of use in pharmaceutically acceptable compositions to treat a subject in need of AAT therapy or treatment. Compositions and methods disclosed herein concern linking AAT or derivative thereof to an immune fragment. | 2014-11-27 |
20140348860 | MEDICAL DEVICES FOR COLLECTING PATHOGENIC CELLS - Disclosed is a medical device constructed and arranged for contact with a flow of blood or other bodily fluid of a patient and including an attached binding agent or a roughened surface that binds to pathogenic cells targeted for elimination from the blood or other bodily fluid. Also disclosed are methods for making and using the device. | 2014-11-27 |
20140348861 | SYNTHETIC PEPTIDES AND RANDOM COPOLYMERS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS - Synthetic peptides and peptide copolymers for amelioration of autoimmune neurological syndrome, inflammatory and/or demyelinating conditions such as encephalomyletis are provided herein. The synthetic peptides and peptide copolymers as disclosed are obtained by substitution of at least one alpha amino acid by beta amino acid and/or β3-homo amino acid. | 2014-11-27 |
20140348862 | Prame derived peptides and immunogenic compositions comprising these - The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer. | 2014-11-27 |
20140348863 | CMV ANTIGENS AND USES THEREOF - The present invention relates to immunogenic compositions comprising CMV antigens and methods for preparing compositions that contain CMV antigens. The invention also relates to methods for inducing an immune response to CMV. | 2014-11-27 |
20140348864 | PORCINE CIRCOVIRUS TYPE-2 (PCV2) SUBUNIT VACCINE - A procine circovirus type-2 (PCV2) immunogenic composition includes an antigenic peptide. The antigenic peptide is a non-arginine-rich peptide of a PCV2 open reading frame 2 (ORF2) and/or a recombinant fusion protein having the non-arginine-rich peptide of the PCV2 ORF2, a PE peptide, and a KDEL signal peptide. The number of arginines of the non-arginine-rich peptide of the PCV2 ORF2 is not greater than half of the number of arginines of the arginine-rich domain of the N terminal of the PCV2 ORF2. | 2014-11-27 |
20140348865 | IMMUNOGENS BASED ON AN HIV-1 V1V2 SITE-OF-VULNERABILITY - Disclosed are HIV immunogens. Also disclosed are nucleic acids encoding these immunogens and methods of producing these antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject. | 2014-11-27 |
20140348866 | GB VIRUS C (HEPATITIS G VIRUS) FOR THE TREATMENT OF HIV - GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections. | 2014-11-27 |
20140348867 | Isolated Brachyspira and Methods and Compositions for Expanding and Isolating Brachyspira - The disclosure provides isolated—, compositions comprising—and methods of culturing —a | 2014-11-27 |
20140348868 | COMPOSITIONS COMPRISING PNEUMOCOCCAL ANTIGENS - Disclosed herein are various combinations of pneumococcal polypeptides for use in immunisation. Also disclosed herein are pneumococcal polypeptides that may be useful as single antigens. These polypeptides may optionally be used in combination with pneumococcal saccharides. The antigens may be used in pneumococcal vaccines, but may also be used as components in vaccines for immunising against multiple pathogens. | 2014-11-27 |
20140348869 | MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES - The factor H binding activity of meningococcal fHBP can be uncoupled from its bactericidal sensitivity. NMR studies have identified various amino acid residues involved in the fHBP/fH interaction and one or more of these residues is modified in a fHBP to reduce or eliminate its ability to bind to fH. | 2014-11-27 |
20140348870 | IMMUNOGENIC PLASMODIUM FALCIPARUM ANTIGEN COMPOSITIONS AND USES THEREOF - Contemplated compositions and methods employ selected antigens form | 2014-11-27 |
20140348871 | Composition Comprising the Amyloid Beta 1-6 Peptide Coupled to a Virus-Like Particle and an Adjuvant - The present invention relates to compositions comprising a construct comprising the Aβ1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type. | 2014-11-27 |
20140348872 | COMPOSITIONS AND METHODS FOR ESTABLISHING AND/OR MAINTAINING PREGNANCY - The present invention relates to compositions comprising selenium (e.g., organic selenium (e.g., selenized yeast (e.g., SEL-PLEX))) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment). For example, the present invention provides compositions comprising selenium (e.g., organic selenium (e.g., selenized yeast (e.g., SEL-PLEX))) and methods of using the same for treating and/or preventing one or more conditions (e.g., problems) disorders, and/or diseases related to establishing and/or maintaining a pregnancy. Compositions and methods of the present invention find use in, among other things, research and clinical (e.g., preventative and therapeutic) applications. | 2014-11-27 |
20140348873 | Urea-Silicone Gel for Hyperkeratosis Treatment - Compositions and methods for urea silicone gels for treating hyperkeratotic skin diseases that may benefit from barrier protection and from urea silicone gel's ability to return water balance to the skin are disclosed. Skin conditions that may be treated with urea silicone gels may be excessive dryness, callus, corns, old and new scars, and keloids, among others. Disclosed urea silicone gels may include micronized urea USP, and an anhydrous silicone base, among other ingredients. Anhydrous silicone base may include Amazonian oils such as pracaxi oil and seje oil, which are rich in oleic, linolenic, linoleic acids, and sterols, particularly beta-sitosterol and stigmasterol, which may increase skin permeability to urea. Additionally, because of the high content of unsaturated fatty acids of pracaxi oil and seje oil, disclosed urea silicone gel may exhibit an enhanced hydrating effect on skin cells, over-moisturizing and hydrating tough, thick hyperkeratotic conditions. | 2014-11-27 |
20140348874 | METHOD FOR THE REDUCTION OF PCV-2 IN A HERD OF SWINE - The present invention relates to a PCV2 ORF2 protein for use in a method for the reduction of the viral load, for the reduction of the infection quota and/or the reduction of the infection pressure in a herd of swine caused by an infection with PCV2. In particular, the present invention relates to any method described above, wherein said PCV2 ORF2 protein is to be administered at regular intervals to female animals of a herd and to piglets. | 2014-11-27 |
20140348875 | KOI HERPESVIRUS VACCINE - The present invention relates to a recombinant Koi herpesvirus (KHV), methods for the production of such KHV, cells comprising such KHV and the use of such KHV as vector and in vaccines for the prevention and/or therapeutic treatment of a disease in fish caused by Koi herpesvirus in carp such as | 2014-11-27 |
20140348876 | Stable Aqueous Formulations of Adenovirus Vectors - The present invention is based on the surprising discovery that the inclusion of an anionic polymer in the adenovirus formulation enhances long-term stability of the vector composition. An aqueous formulation comprising an adenovirus vector and at least one anionic polymer is provided, together with methods of the preparation of a storage stable adenovirus aqueous formulation. | 2014-11-27 |
20140348877 | Lobster hemolymph as a utility for treatment of mammalian tissue lesions - The invention is crustacean hemolymph as a utility for the pharmaceutical and/or cosmetic treatment of viral and other neoplastic or pre-neoplastic mammalian tissue lesions. The method comprises topically administering to mammalian tissue a formula that is made from lobster hemolymph—neat; or lobster hemolymph extracts; or lobster hemolyph in combination with certain carriers, binders; or as an adjuvant. The hemolymph may be from various species of lobster, | 2014-11-27 |
20140348878 | STRAIN OF EXOPOLYSACCHARIDE-SECRETING LACTOBACILLUS BREVIS AND APPLICATION THEREOF - A strain of exopolysaccharide-secreting | 2014-11-27 |
20140348879 | ENTERIC SOFT CAPSULES - A gel mass is provided that is useful for manufacturing enteric soft capsules without coating. | 2014-11-27 |
20140348880 | Ortho-Aminothiophenol Compounds and Uses Thereof - A method for treating or preventing a microbial infection in a subject in need thereof, the method comprising administering to the subject, a therapeutically effective amount of a compound of Formula Ia, a compound of Formula IIa, one or more compounds of Formula Ia or Formula IIa complexed with a metal core, or a pharmaceutically acceptable salt, prodrug or hydrate thereof. | 2014-11-27 |
20140348881 | METHOD FOR DIAGNOSING AND TREATING DYSAUTONOMIA AND OTHER DYSAUTONOMIC CONDITIONS - A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder. | 2014-11-27 |
20140348882 | IN VIVO DELIVERY OF NUCLEIC ACIDS TO THE LIVER OR LIVER TISSUE - The invention encompasses methods of delivering nucleic acids, including dsRNA, to mammalian target cells in vivo via intercellular transfer, wherein the dsRNA is delivered to or expressed in a first cell different from the target cell, wherein the first cell facilitates delivery of the dsRNA to the target cell. | 2014-11-27 |
20140348883 | COMPOSITIONS AND METHODS FOR ENHANCING BRAIN FUNCTION - A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola. The composition is formulated for oral administration. The huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola are in a ratio a:b:c:d: respectively such that a as the huperzine A is between about 0.8 and 1.2, b as vinpocetine is between about 80 and 120, c as rhodiola is about 1,600 and 2,400, and d as the acetyl-L-carnitine is between about 8,000 and 12,000. | 2014-11-27 |
20140348884 | SHAMPOO COMPOSITION WITH ASSOCIATIVE THICKENERS - A shampoo composition with improved in use hair feel, comprising associative thickeners and liquid crystals formed from anionic surfactants and polyDADMAC and wherein the liquid crystals have a particle size greater than about 1 micrometer. | 2014-11-27 |
20140348885 | MASS PREPARATION METHOD FOR SPHERICAL NATURAL COLOR WAX BEADS - This invention relates to a mass preparation method of spherical natural color wax beads and according to the invention, the beads have a higher specific gravity than water so that the beads do not flow into the sea and they are biodegradable to fundamentally remarkably reduce marine ecosystem contamination, and it enables mass preparation by significantly improving the previous preparation of spherical natural color wax beads which had difficulties in their mass preparation while using expensive equipment. | 2014-11-27 |
20140348886 | Method of Achieving Improved Product Rheology, Cosmetic Consumer Acceptance and Deposition - A method of achieving improved composition rheology, cosmetic consumer acceptance and deposition comprising applying to hair a composition comprising from about 0.01% to about 2% of a cationic polymer; from about 0.5% to 3% of an associative thickener; from about 1.0% to 10.0% of a polyol; an anti-dandruff active; a cosmetically acceptable carrier; a surfactant; wherein the composition comprises a yield consistency value of about 0.001 s to 0.9 s and having a rate index value of from about 0.01 to about 0.6 and a percentage of coacervate particles with a floc size of greater than about 20 microns is from about 1% to about 40%. | 2014-11-27 |
20140348887 | Surfactant Responsive Emulsion Polymerized Micro-Gels - A stable, aqueous composition containing a crosslinked, nonionic, amphiphilic polymer capable of forming a yield stress fluid in the presence of a surfactant is disclosed. The yield stress fluid is capable of suspending insoluble materials in the form of particulates and/or droplets requiring suspension or stabilization. | 2014-11-27 |
20140348888 | COSMETIC COMPOSITION CONTAINING INORGANIC POWDER - The present invention relates to a cosmetic composition comprising: (i) boron nitride; and (ii) one or more kinds of inorganic powders selected from the group consisting of cerium oxide, titanium oxide, talc, aluminum oxide, iron oxide, zinc oxide and mica. UVA, UVB and near-IR may be simultaneously screened by applying the cosmetic composition. | 2014-11-27 |
20140348889 | Compositions and Methods for Treating and Preventing Neointimal Stenosis - Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed. | 2014-11-27 |
20140348890 | WOUND DRESSING - The invention relates to a wound dressing having a backing and an antimicrobial wound contact layer, wherein the wound contact layer has a hydrophobized active ingredient. | 2014-11-27 |
20140348891 | ACTIVE NANOCOMPOSITE MATERIALS AND PRODUCTION METHOD THEREOF - The present invention refers to new active nanocomposite materials, comprising a matrix and additives. The present invention also describes a process for obtaining these nanocomposite materials and their use in various industry sectors. | 2014-11-27 |
20140348892 | Method for manufacturing a parasiticidal composition - A method for manufacturing a parasiticidal composition comprising at least 40% of alkali metal bicarbonate and at least 1% of silica, wherein: at least 35% of the alkali metal bicarbonate of the composition is milled in the presence of silica in order to form a mixture of particles, and if necessary, the remainder of the alkali metal bicarbonate is added to the mixture of particles to form the parasiticidal composition, and wherein said parasiticidal composition has a particle size distribution such that at least 50% by weight of the particles have a diameter of less than 100 μm. A parasiticidal composition obtained by the present method and the use of the parasiticidal composition obtained by the present method in the form of a powder, a suspension or a gel. | 2014-11-27 |
20140348893 | RNAI FOR THE CONTROL OF INSECTS AND ARACHNIDS - The present invention describes a new non-compound based approach for insect and/or arachnid control. The present inventors have identified for the first time novel targets for RNAi, which can effectively control insect and/or arachnid pest populations. Accordingly, the invention provides both nucleotide and amino acid sequences for the novel targets. Also provided are RNA constructs including double stranded RNA regions for mediating RNAi in insects, DNA constructs, expression vectors, host cells and compositions for controlling insects and/or arachnids using RNAi. Finally, the invention also provides for the use of the constructs, vectors, host cells and compositions in control of insects and/or arachnids populations and suitable kits for use in an RNAi based method of controlling insect and/or arachnid pests. | 2014-11-27 |
20140348894 | Engineered Protein Coating for Medical Implants - Engineered protein coatings are provided for medical implants to promote bone regeneration. The coating is an engineered protein containing an elastin-like structural domain (SEQ ID No: 2) and a cell-adhesive domain derived from an extended fibronectin RGD sequence. The surface of the medical implant is covalently and directly bonded to the coating via photoreactive crosslinking through an insertion and/or addition reaction. The engineered protein coating can be applied directly upon fabrication of the implant, which would eliminate applying the coating in the operating room. The engineered protein coating is also customizable and can include biologics to improve performance. Furthermore, the engineered protein coating could also be spatially patterned on the implant surface. | 2014-11-27 |
20140348895 | PARA-XYLENE FILMS AND THERAPEUTIC USES THEREOF - The present invention provides single sheet and compound para-xylene films for therapeutic uses. For example, the present invention provides single sheet para-xylene films useful as tissue separators and/or adhesion barriers in a subject, where the top and/or bottom surfaces of such films have a water contact angle between 75 and 95 degrees (e.g., to prevent adhesion formation). The present invention also provides compound films composed of at least two para-xylene polymer films with a therapeutic molecule layer in between. Such compound films, when used in vivo (e.g., as a tissue separator and to treat inflammation or atrial fibrillation) allow either therapeutic molecule elution through one of the para-xylene layers, or therapeutic molecule release when the compound film is pierced, such as when it is sutured in place. | 2014-11-27 |
20140348896 | Hydrophobic Tissue Adhesives - Pre-polymers for use as tissue sealants and adhesives, and methods of making and using thereof are provided. The pre-polymers have flow characteristics such that they can be applied through a syringe or catheter but are sufficiently viscous to remain in place at the site of application and not run off the tissue. The pre-polymers are also sufficiently hydrophobic to resist washout by bodily fluids. The pre-polymers are stable in bodily fluids; that is the pre-polymer does not spontaneously crosslink in bodily fluids absent the presence of an intentionally applied stimulus to initiate crosslinking. Upon crosslinking, the adhesive exhibits significant adhesive strength in the presence of blood and other bodily fluids. The adhesive is sufficiently elastic that it is able to resist movement of the underlying tissue. The adhesive can provide a hemostatic seal. The adhesive is biodegradable and biocompatible, causing minimal inflammatory response. | 2014-11-27 |
20140348897 | TREATMENT OR REDUCTION OF DENTAL CONDITIONS WITH ASCORBYL ESTERS - The present disclosure provides methods and compositions comprising ascorbyl esters for the treatment or reduction of dental conditions in an animal. A pet food composition of the disclosure can be a dry food composition comprising (i) a matrix of ingredients nutritionally or organoleptically adapted for the animal and (ii) an outer coating layer, wherein the outer coating layer is applied to the matrix as a solution comprising an effective amount of an ascorbic acid fatty acid ester dissolved in a plant oil. One disclosed method of treatment or reduction involves feeding an animal in need of such treatment a dry pet food composition of the disclosure. A second disclosed method comprises applying to one or more surfaces of one or more teeth of an animal in need of such treatment, an effective amount of a solution comprising an ascorbic acid fatty acid ester dissolved in a plant oil. | 2014-11-27 |
20140348898 | LOCAL ADMINISTRATION OF GALLIUM COMPOSITIONS TO TREAT PAIN - Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms. | 2014-11-27 |
20140348899 | METHOD AND COMPOSITION FOR TREATING CYSTITIS - A medicament for treating cystitis and a method of treatment are provided. The medicament comprises a stromal vascular fraction provided in a liposomal carrier. Optionally, the medicament also controls one or more additional agents, such as a growth factor, glycosaminoglycan, DMSO, and/or another small molecule used to treat cystitis or having an effect on human stem cells. Cystitis is treated by intravesically administering to a patient a therapeutically effective dose of the medicament. The SVF can be derived from a patient's own adipose cells via liposuction. | 2014-11-27 |
20140348900 | METHODS AND DEVICES FOR PREPARATION OF LIPID NANOPARTICLES - The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions. | 2014-11-27 |
20140348901 | COMBINATORIAL METHODS AND COMPOSITIONS FOR TREATMENT OF MELANOMA - The invention relates to combining targeted therapies with selected chemotherapeutics for the treatment of melanoma. The invention provides a method for inducing apoptosis in a melanoma tumor cell by reducing Akt3 activity, a method for inducing apoptosis in a melanoma tumor cell comprising contacting a melanoma tumor cell with an agent that reduces Akt3 activity to restore normal apoptotic sensitivity to a melanoma tumor cell, allowing a lower concentration of chemotherapeutic agents resulting in decreased toxicity to a patient. Also disclosed is a method for treating a melanoma comprising administering an agent that reduces Akt3 activity and an agent that reduces V599E B-Raf activity, thereby treating a melanoma tumor. | 2014-11-27 |
20140348902 | TCL1 PEPTIDES FOR IMMUNOTHERAPY - Provided are TCL1 peptides that bind to MHC I (HLA-A2) on tumor cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The TCL1 peptides may be therapeutically used to treat a cancer, such as a B cell malignancy, leukemia, or lymphoma. Methods for expanding a population of T cells that target TCL1 are also provided. | 2014-11-27 |
20140348903 | ROBUST CONTROLLED-RELEASE FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of: a. at least one diacyl glycerol and/or at least one tocopherol; b. at least one phospholipid component comprising phospholipids having i. polar head groups comprising more than 50% phosphatidyl ethanolamine, and ii. two acyl chains each independently having 16 to 20 carbons wherein at least one acyl chain has at least one unsaturation in the carbon chain, and there are no more than four unsaturations over two carbon chains; c. at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein optionally at least one bioactive agent is dissolved or dispersed in the low viscosity mixture; and wherein the pre-formulation forms, or is capable of forming, at least one non-lamellar liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations. | 2014-11-27 |
20140348904 | Exosomes With Transferrin Peptides - The present invention relates to exosomes comprising a transferrin targeting moiety on their surface, methods of producing them and to the use of such exosomes for delivering genetic material and/or biotherapeutic proteins or peptides or chemotherapeutic agents in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing, or delivery of other therapeutic agents. | 2014-11-27 |
20140348905 | GEL COMPOSITIONS - The present invention relates to a topical gel composition comprising ingenol-3-angelate, wherein the composition provides greater flux, according to the in vitro diffusion test, of ingenol-3-angelate into the stratum corneum, epidermis and dermis after application of the gel composition to skin than does a reference gel of ingenol-3-angelate, namely the PICATO® product. | 2014-11-27 |
20140348906 | IMMUNOSTIMULATORY COMPOSITIONS COMPRISING LIPOSOME-ENCAPSULATED OLIGONUCLEOTIDES AND EPITOPES - The present invention relates to a composition for enhancing an immune response, an epitope having immunogenicity, screening and preparing method thereof, a antibody to peptide antigen and screening and preparing method thereof. The composition of the present invention may be effectively used for preventing or treating diverse immune-deficiency diseases such as cancer, influenza virus, hepatitis C virus and RSV (respiratory syncytial virus) by enhancing immune responses. | 2014-11-27 |
20140348907 | METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES - The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays. | 2014-11-27 |
20140348908 | METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES - The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays. | 2014-11-27 |
20140348909 | PHARMACEUTICAL COMPOSITIONS OF LURASIDONE - The present invention relates to pharmaceutical compositions of lurasidone or salts thereof. In particular, the invention relates to pharmaceutical compositions of lurasidone or salts thereof with one or more water-insoluble pharmaceutical excipients. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of schizophrenia, bipolar disorders or senile dementia. | 2014-11-27 |
20140348910 | Topical Formulations Including Lipid Microcapsule Delivery Vehicles and Their Uses - The present invention relates to topical formulations that include lipid microcapsules formed from tocopherol, tocotrienol, or mixtures thereof; a stabilizer/surfactant component; and an aqueous component. The lipid microcapsules may be formed without the use of steroids, preservatives, initiators and/or oils. The topical formulations are capable of delivering transdermal active agent(s) such as vitamin D through the skin and into the bloodstream without the use of skin penetration enhancers. In certain embodiments, the topical formulations also able to deliver topical active agent(s) such as sun-protecting agents to the surface of the skin where they remain, while simultaneously delivering the transdermal active agent(s) through the skin and into the bloodstream. | 2014-11-27 |
20140348911 | SPRAY FORMULATION OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF CHRONIC WOUNDS - The present Invention describes therapeutic and medical applications of Mesenchymal Stem Cells, by means of fine mist spraying application system. The mesenchymal stem cells used in the fine mist spray application system are in suspension and may optionally be nanoencapsulated or not. | 2014-11-27 |
20140348912 | CAPSULE FOR ENCAPSULATING A TABLET - A capsule for encapsulating a tablet, includes two capsule portions of equal sizes and dimensions, each containing a moisture content of 12 to 16% and having a plurality of ridges projecting inwardly from the inner circumference of the respective capsule portions and extending along the inner circumference of the respective capsule portions in radially spaced apart relationship with one another and defining fluid flow passages between the ridges. The outline defined by the tips of the ridges correspond to the outer surface of the tablet to provide an interference fit between the ridges and the tablet when the capsule portions are push fitted over the tablet from the ends of the tablet in an abutting but not overlapping relationship with each other at ambient conditions. | 2014-11-27 |
20140348913 | BITTER CRUDE DRUG-COMPRISING GRANULAR PRODUCT - Provided is a granular product that has reduced or suppressed bitterness even though comprising a bitter crude drug or an extract thereof, and that allows a pharmacological action of the bitter crude drug to be sufficiently expressed. The granular product comprises a bitter crude drug or an extract thereof in each of the inner part and outer layer of the granular product. | 2014-11-27 |
20140348914 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof - Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed. | 2014-11-27 |
20140348915 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof - Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed. | 2014-11-27 |
20140348916 | Treatment of Pain with Oral Dosage Forms Comprising Zoledronic Acid and An Enhancer - Disclosed herein are methods of treating or preventing pain. Typically, a pharmaceutical composition having a therapeutically effective amount of the zoledronic acid is administered to a mammal suffering from pain. The pharmaceutical composition may further comprise an enhancer, which can be a medium chain fatty acid salt, an ester, an ether, or a derivative of a medium chain fatty acid and can have a carbon chain length of from about 4 to about 20 carbon atoms. | 2014-11-27 |
20140348917 | IMMEDIATE RELEASE FORMULATIONS AND DOSAGE FORMS OF GAMMA-HYDROXYBUTYRATE - The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form. | 2014-11-27 |
20140348918 | DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF ASTHMA - The present invention refers to the treatment of asthma by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof. | 2014-11-27 |
20140348919 | ANTIBIOTIC COMPOUNDS - This invention relates to novel purified compounds of Formula I. The invention includes all stereoisomeric forms and all tautomeric forms of the compounds of Formula I and pharmaceutically acceptable salts and derivatives. The present invention further relates to processes for the production of the novel antibacterial compounds by fermentation of the microorganism belonging to | 2014-11-27 |
20140348920 | Method of Treating Multiple Sclerosis - The invention provides methods for treating multiple sclerosis by administering biotin. The invention also provides methods for treating sequelae after multiple sclerosis attacks by administering biotin. | 2014-11-27 |
20140348921 | NOVEL HEMOSTATIC COMPOSITION - The present invention relates to a novel hemostatic composition notably useful to ensure good hemostasis and maintain the sulcular opening after a gingival eviction procedure. | 2014-11-27 |
20140348922 | PROCESS FOR PRODUCING A PARTICULATE COMPOSITION COMPRISING AN HYDROUS CRYSTALLINE 2-O-ALPHA-D-GLUCOSYL-L-ASCORBIC ACID - The invention provides a process for enabling the production of a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside that does not significantly cake even when the production yield of ascorbic acid 2-glucoside does not reach 35% by weight. The process for producing a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside, which comprises allowing a CGTase to act on a solution containing either liquefied starch or dextrin and L-ascorbic acid and then allowing a glucoamylase to act on the resulting solution to obtain a solution with an ascorbic acid 2-glucoside production yield of at least 27%, purifying the obtained solution to increase the ascorbic acid 2-glucoside content to a level of over 86% by weight, precipitating anhydrous crystalline ascorbic acid 2-glucoside by a controlled cooling method or pseudo-controlled cooling method, collecting the precipitated anhydrous crystalline ascorbic acid 2-glucoside, and ageing and drying the collected anhydrous crystalline ascorbic acid 2-glucoside. | 2014-11-27 |
20140348923 | Polymeric Drug-Delivery Material, Method For Manufacturing Thereof And Method For Delivery Of A Drug-Delivery Composition - A method for manufacturing a drug-delivery composition includes providing at least one pharmaceutically active compound, a dry powder comprising at least a polymer, and an aqueous solution. The dry powder, the pharmaceutically active compound and the aqueous solution are mixed to form a paste-like or semi-solid drug-delivery composition, wherein the aqueous solution is added in an amount of less than or equal to twice the total dry mass of the dry powder. | 2014-11-27 |
20140348924 | PARTICLES COMPRISING SINGLE STRANDED RNA AND DOUBLE STRANDED RNA FOR IMMUNOMODULATION - The present invention relates to chimeric particles comprising single stranded RNA (ssRNA), double stranded RNA (dsRNA) and at least one cationic agent, a pharmaceutical composition containing said particles and to a method of producing the same. The particles of the present invention are particularly useful as an immunostimulating medicament with a superlative pattern of immunostimulation. | 2014-11-27 |
20140348925 | Antioxidant Ingredient With Low Calorie Content, Method for Obtaining Same and Use Thereof - The present invention relates to an antioxidant ingredient with low calorie content obtainable by a process that comprises the following steps: (a) selecting as raw material at least one fruit and/or plant material with high antioxidant content, greater than 6 g/100 g dry matter; (b) obtaining juice and pulp by means of grinding, squeezing and/or pressing the raw material; (c) extracting sugars from the pulp obtained in the preceding step in order to produce a pulp with low calorie content; (d) dehydrating the pulp by means of a method selected from air drying, low-temperature drying with application of vacuum and/or freeze-drying; and (e) milling the pulp in order to produce the antioxidant ingredient with low calorie content. Likewise, the invention relates to the process for obtaining said ingredient and to the use thereof for the production of functional foods. | 2014-11-27 |
20140348926 | FORMULATION AND METHOD FOR INCREASING ORAL BIOAVAILABILITY OF DRUGS - The application discloses a formulation and method for increasing bioavailability of an orally administered drug. | 2014-11-27 |
20140348927 | CONDITIONING HAIR-CLEANING AGENT - Cosmetic cleaning agents include in a cosmetically acceptable carrier a) at least one anionic surfactant, b) at least one cationic guar polymer, c) at least one silicone emulsion, in which the silicone particles have an average diameter of a maximum of 600 nm, and d) at least one wax. The cosmetic cleaning agents are suitable in particular for use as a shampoo. After application they impart improved properties to the hair treated therewith, in particular improved wet and dry combability. | 2014-11-27 |
20140348928 | SUBSTITUTED N-ARYL PYRIDINONES - Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 2014-11-27 |
20140348929 | Omega-3 Fatty Acid Ester Compositions - Described herein are compositions comprising at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions. | 2014-11-27 |